Cell therapy special: best of 2018

This week in cell therapy: we look back at the most read cell therapy news from 2018, including acquisitions, production troubles and regulator raids on both sides of the Pacific.

Dec 13, 2018

FebruaryMarchAprilMayJuneJuly AugustSeptemberOctoberNovember

Cord blood demonstrated to be safe and improve children with autism

In research funded by the Cord Blood Registry and published in February in Stem Cells Translational Medicine, treatment of autistic children with their own newborn cord blood was found to be safe and led to improvements in test scores for socialization.

Read more

First allogeneic stem cell therapy approved for use in EU

In March, TiGenix (Belgium) and Takeda’s (Osaka, Japan) Alofisel was approved by the European Commission for the treatment of complex perianal fistulas in adult Crohn’s disease sufferers, making it the first allogeneic stem cell-based therapy to receive approval for marketing in Europe.

Read more

Roche acquires MS program

In April, Roche Holdings Inc. (Switzerland) acquired Inception 5, a program focused on discovering regenerative therapies for multiple sclerosis.

Read more

FDA files for permanent injunctions against two for-profit stem cell clinics

May brought news that the FDA filed two permanent federal injunctions against clinics marketing and providing unapproved stem cell treatments. US Stem Cell Clinic LLC (FL, USA) and California Stem Cell Treatment Center Inc. (CA, USA) were served the injunctions to cease marketing their stem cell products until the necessary approvals were obtained and violations of good manufacturing practice were corrected.

Read more

Point-of-care CAR-T therapy placed on clinical hold

In June, the FDA placed a clinical hold on a Phase 1 trial evaluating a CD19-specific CAR-T therapy manufactured at the point of care, pending additional information relating to chemistry, manufacturing and controls in support of the investigational new drug application from Ziopharm Oncology, Inc. (MA, USA).

Read more

Novartis faces production glitch over Kymriah

In this news from July, Novartis revealed that during the translation of Kymriah from clinical trial to commercial production, the minimum percentage of viable cells had not been met, prompting a statement from Novartis and FDA involvement.

Read more

Platelet-rich plasma does not promote regenerative capabilities of MSCs

In research published in August, platelet-rich plasma (PRP), which is commonly used in commercially available regenerative medicine treatments, often for degenerative joint indications, was found to impair cartilage formation in the long term.

Read more

Spray-on skin receives FDA approval

September brought news that the RECELL® System, developed by AVITA Medical (VIC, Australia), was approved by the FDA for the treatment of second- and third-degree burns.

Read more

Korean regulator raids four manufacturers

In October, the Korean regulator, the Ministry of Food and Drug Safety, recently conducted “urgent inspections” of four manufacturers of cell therapy over concerns over a possible change in cell source or donor.

Read more

StemGenex receives warning letter from FDA

In more FDA action, StemGenex Biologic Laboratories LLC (CA, USA) has received a warning from the FDA in November over marketing of a ‘stem cell’ product that hasn’t received FDA approval as well as “significant deviations” from good manufacturing practice (GMP) at their manufacturing facility.

Read more

From everyone at RegMedNet, wishing you season's greetings and a happy 2019, full of regenerative medicine and cell therapy news!


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.